Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (61-70 of 187) with videos related to

Pageof 19
Sort By:
European Journal of Haematology|July 15, 2026
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM TrialsFrancesca Palandri, Casey O'Connell, Pankit Vachhani, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Annals of Hematology|September 20, 2025
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registriesMassimo Breccia, Simone Celant, Francesca Palandri, et al.
European Journal of Haematology|October 14, 2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of SurvivalHelen Ajufo, Jan Philipp Bewersdorf, Claire Harrison, et al.
Annals of Hematology|May 21, 2024
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomesFrancesca Palandri, F Branzanti, M Venturi, et al.
Cancers|October 13, 2021
A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia VeraMartina Barone, Monica Barone, Francesca Ricci, et al.
European Journal of Haematology|December 17, 2016
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term responseMiriam Marangon, Nicola Vianelli, Francesca Palandri, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Future Oncology (London, England)|March 7, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinibPankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, et al.
Pageof 19

Showing results (61-70 of 187) with videos related to

Sort By:
Pageof 19
European Journal of Haematology|July 15, 2026
Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM TrialsFrancesca Palandri, Casey O'Connell, Pankit Vachhani, et al.
Annals of Hematology|May 28, 2018
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trialMartin Griesshammer, Guray Saydam, Francesca Palandri, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Annals of Hematology|September 20, 2025
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registriesMassimo Breccia, Simone Celant, Francesca Palandri, et al.
European Journal of Haematology|October 14, 2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST-2 Landmark Analysis of SurvivalHelen Ajufo, Jan Philipp Bewersdorf, Claire Harrison, et al.
Annals of Hematology|May 21, 2024
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomesFrancesca Palandri, F Branzanti, M Venturi, et al.
Cancers|October 13, 2021
A Specific Host/Microbial Signature of Plasma-Derived Extracellular Vesicles Is Associated to Thrombosis and Marrow Fibrosis in Polycythemia VeraMartina Barone, Monica Barone, Francesca Ricci, et al.
European Journal of Haematology|December 17, 2016
Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term responseMiriam Marangon, Nicola Vianelli, Francesca Palandri, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Future Oncology (London, England)|March 7, 2026
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinibPankit Vachhani, Abdulraheem Yacoub, Raajit Rampal, et al.
Pageof 19